BofA upgrades Axsome to buy, cites upcoming Auvelity data
AXSM Stock | USD 91.94 0.00 0.00% |
About 52% of Axsome Therapeutics' investors are presently thinking to get in. The analysis of overall sentiment of trading Axsome Therapeutics stock suggests that some investors are interested at this time. Axsome Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Axsome Therapeutics. Many technical investors use Axsome Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Axsome |
BofA has upgraded Axsome to buy, citing the revenue potential of its drug Auvelity ahead of upcoming Phase 3 data. Read more here.
Read at seekingalpha.com
Axsome Therapeutics Current Investor Sentiment
Panic Vs Confidence
52
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Axsome Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Axsome Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Axsome Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Axsome Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Axsome Therapeutics Historical Investor Sentiment
Investor biases related to Axsome Therapeutics' public news can be used to forecast risks associated with an investment in Axsome. The trend in average sentiment can be used to explain how an investor holding Axsome can time the market purely based on public headlines and social activities around Axsome Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Axsome Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Axsome Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Axsome Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Axsome Therapeutics.
Axsome Therapeutics Maximum Pain Price Across March 21st 2025 Option Contracts
Axsome Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Axsome Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Axsome Therapeutics' options.
Axsome Therapeutics Fundamental Analysis
We analyze Axsome Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Axsome Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Axsome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Axsome Therapeutics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Axsome Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Axsome Therapeutics stock to make a market-neutral strategy. Peer analysis of Axsome Therapeutics could also be used in its relative valuation, which is a method of valuing Axsome Therapeutics by comparing valuation metrics with similar companies.
Peers
Axsome Therapeutics Related Equities
AKRO | Akero Therapeutics | 4.71 | ||||
AMLX | Amylyx Pharmaceuticals | 2.86 | ||||
TGTX | TG Therapeutics | 1.41 | ||||
PDSB | PDS Biotechnology | 1.40 | ||||
DAWN | Day One | 1.13 | ||||
SRPT | Sarepta Therapeutics | 0.80 | ||||
ACAD | ACADIA Pharmaceuticals | 0.29 | ||||
VKTX | Viking Therapeutics | 0.28 | ||||
BPMC | Blueprint Medicines | 0.00 | ||||
MDGL | Madrigal Pharmaceuticals | 0.00 | ||||
HEPA | Hepion Pharmaceuticals | 0.21 | ||||
MCRB | Seres Therapeutics | 0.39 | ||||
INCY | Incyte | 0.75 | ||||
TERN | Terns Pharmaceuticals | 1.56 |
Check out Axsome Therapeutics Hype Analysis, Axsome Therapeutics Correlation and Axsome Therapeutics Performance. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.58) | Revenue Per Share | Quarterly Revenue Growth 0.813 | Return On Assets | Return On Equity |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.